Status | Study |
NOT_YET_RECRUITING |
Study Name: Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial Condition: Date: 2023-06-02 Interventions: Undergo bone marrow biopsy |
Not yet recruiting |
Study Name: Study in Subjects With Light Chain (AL) Amyloidosis Condition: AL Amyloidosis Date: 2017-04-28 Interventions: Drug: NEOD001 humanized monoclonal antibody |
Not yet recruiting |
Study Name: Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis Condition: Amyloidosis Immunoglobulin Light Chain Deposition Date: 2017-04-21 Interventions: Drug: Bortezomib Given SC |
Recruiting |
Study Name: Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis Condition: AL Amyloidosis Date: 2016-12-12 Interventions: Drug: Venetoclax Venetoclax at |
Not yet recruiting |
Study Name: Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients Condition: Amyloidosis; Systemic Date: 2016-11-18 Interventions: Drug: Propylene Glycol-Free Melphalan Hydrochloride Intravenous Propylene Glycol-Free Melphalan Hydrochl |
Active, not recruiting |
Study Name: Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. Condition: Multiple Myeloma Amyloidosis Date: 2016-09-19 Interventions: Device: Melphalan Drug: Pegfilgrastim |
Recruiting |
Study Name: Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis Condition: Amyloidosis Date: 2016-06-22 Interventions: Drug: Daratumumab |
Recruiting |
Study Name: Daratumumab for the Treatment of Patients With AL Amyloidosis Condition: AL Amyloidosis Date: 2016-06-14 Interventions: Drug: daratumumab Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four mon |
Recruiting |
Study Name: A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early Condition: Plasma Cell Dyscrasia Monoclonal Gammopathy Date: 2016-04-11 |
Recruiting |
Study Name: Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis Condition: Amyloidosis Date: 2016-03-14 Interventions: Other: blood collection Other: bone marrow |